Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25659967 | 0.92 | KLKB1 (0.42) | KLKB1RIPK1 | |
| SCHEMBL24863505 | 0.91 | KLKB1 (0.43) | KLKB1GRM2P2RX3NPC1LMNA | |
| SCHEMBL24863530 | 0.88 | KLKB1 (0.37) | KLKB1RIPK1 | |
| SCHEMBL24863509 | 0.85 | KLKB1 (0.38) | KLKB1GRM2 | |
| SCHEMBL25659769 | 0.85 | KLKB1 (0.46) | KLKB1 | |
| SCHEMBL25659947 | 0.84 | ELANE (0.37) | KLKB1GRM2NPC1LMNARAB9A | |
| SCHEMBL24863354 | 0.83 | CA12 (0.36) | KLKB1GRM2NPC1LMNARAB9A | |
| SCHEMBL24863355 | 0.82 | LMNA (0.38) | KLKB1NPC1LMNA | |
| SCHEMBL25659886 | 0.81 | KLKB1 (0.38) | KLKB1LMNA | |
| SCHEMBL25659772 | 0.80 | KLKB1 (0.32) | KLKB1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814371-B2 | Heterocyclic compound | MEDSHINE DISCOVERY INC. (CN) | 2023-11-14 | — | — | US | disclosed |
| EP-4116299-A1 | HETEROCYCLIC COMPOUND | Medshine Discovery Inc. (CN) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814371-B2 | Heterocyclic compound | CYP11B2, CYP4F11, CYP11B1 | KLKB1 1724/4885GRM2 4240/4885RIPK1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.